DynamicIQ enables visualization and quantification of PET tracer pharmacokinetics based on whole body dynamic PET images. PET tracer pharmacokinetics include the physiological parameters of tracer uptake rate of the tracer and total blood distribution volume (Vd) that allow for analyzing the tracer accumulation over time, providing additional information that may help in the evaluation of SUV measurements on PET static images. The output of DynamicIQ is intended to be used by appropriately trained healthcare professionals as adjunct information for the review, analysis, and communication of PET static images for diagnosis, staging, treatment planning and monitoring. The parametric images should always be considered in addition to the conventional static PET images, which are the primary source to assist with diagnosis.

Device Description

DynamiclQ is a post processing and visualization for visualizing and quantifying dynamic and static PET DICOM series. The software provides FDG tracer pharmacokinetics by generation of parametric images based on dynamic PET scans. The parametric images include physiological parameters of tracer uptake rate (Ki), metabolic rate of FDG and total blood distribution volume (Vd). In addition to the FDG Tracer pharmacokinetics, the software also performs the conventional review, analysis and communication of conventional PET static images, CT and MR images.

DynamicIQ assists with the clinical workflow by providing adjunct information of FDG tracer pharmacokinetics along with conventional PET static images for cross reference. The adjunct information of FDG tracer pharmacokinetics also help with analyzing the images that could have variability of quantitative measurements due to differences in uptake time, patient body size and blood glucose levels, leading to better characterization of tracer uptake compared to SUV alone.

AI/ML Overview

The provided text describes the regulatory submission for DynamicIQ, a post-processing and visualization software for PET images. It mentions a study for performance testing but does not provide specific details on the acceptance criteria, reported performance values, or the study design.

Therefore, I cannot fulfill your request for:

A table of acceptance criteria and reported device performance.
Sample sizes for test set, data provenance, number of experts for ground truth, expert qualifications, or adjudication methods for the test set.
Information on a multi-reader multi-case (MRMC) comparative effectiveness study or standalone performance.
Specifics on the type of ground truth used.
Sample size or ground truth establishment for the training set.

The document states that "DynamicIQ has successfully completed the design control testing per GE's quality system. It was designed and will be manufactured under the Quality System Regulations of 21CFR 820 and ISO 13485. No additional hazards were identified, and no unexpected test results were observed." It also mentions "Performance testing (Verification, Validation)" and "Safety Testing (Verification)" were applied. This confirms that studies were conducted to ensure the device meets its design requirements and safety standards, but no specific details of those studies are included in this FDA 510(k) summary.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath.

November 22, 2022

GE Medical Systems SCS % Tong Zhao Regulatory Affairs Leader 283, rue de la Miniere Buc, 78530 FRANCE

Re: K222895

Trade/Device Name: DynamicIQ Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: Class II Product Code: KPS, LLZ Dated: September 21, 2022 Received: September 23, 2022

Dear Tong Zhao:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

{1}------------------------------------------------

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Daniel M. Krainak, Ph.D. Assistant Director Magnetic Resonance and Nuclear Medicine Team DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K222895

Device Name

DynamicIQ

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

{3}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for General Electric (GE). The logo consists of the letters "GE" in a stylized script, enclosed within a blue circle. There are decorative swirls around the circle, giving it a classic and recognizable appearance. The logo is simple, yet distinctive, and is widely associated with the multinational conglomerate.

K222895

510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

Date:	September 21, 2022
Submitter:	GE Medical Systems SCSEstablishment Registration Number - 9611343283 rue de la Miniere78530 Buc, France
Primary Contact Person:	Tong ZhaoRegulatory Affairs LeaderGE Healthcare(+86) 15142077290Email: Tong.Zhao2@ge.com
Secondary Contact Person:	Elizabeth MathewSenior Regulatory Affairs ManagerGE HealthcareTel:(262)424-7774Email: Elizabeth.Mathew@ge.com
Device Trade Name:	DynamicIQ
Common/Usual Name:	DynamicIQ
Primary Regulation Number:	Emission computed tomography system (21 CFR 892.1200)
Primary Product Code:	KPS
Secondary Product Code:	LLZ
Classification:	Class II

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows the logo for General Electric (GE). The logo consists of the letters "GE" in a stylized, cursive font, enclosed within a blue circle. There are also some white swirls around the letters, adding a dynamic element to the design. The logo is simple, recognizable, and has been used by GE for many years.

Predicate Device
Device name:	Biograph Horizon PET/CT
Manufacturer:	Siemens Medical Solutions USA, Inc.
510(k) number:	K193178
Regulation Number:	21 CFR 892.1200 Emission computed tomography system
	21 CFR 892.1750 Computed Tomography X-Ray System
Product Code:	KPS, JAK
Classification:	Class II
Reference Devices
Device name:	PET VCAR
Manufacturer:	GE Medical Systems SCS
510(k) number:	K211247
Regulation Number:	21 CFR 892.1200 Emission computed tomography system
	21 CFR 892.2050 Medical image management and processing system
Product Code:	KPS, LLZ
Classification:	Class II

Device Description:

{6}------------------------------------------------

Image /page/6/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" in a stylized, cursive font, enclosed within a blue circle. There are decorative swirls or flourishes around the circle, adding a touch of elegance to the design. The logo is simple, recognizable, and has been used by GE for many years.

Intended Use:

DynamiclQ enables visualization and quantification of PET tracer pharmacokinetics based on whole body dynamic PET images. The output of DynamiclQ is intended to be used by appropriately trained healthcare professionals as adjunct information for the review, analysis, and communication of conventional static PET images for diagnosis, staging, treatment planning and monitoring.

Indication for Use:

DynamiclQ enables visualization and quantification of PET tracer pharmacokinetics based on whole body dynamic PET images. PET tracer pharmacokinetics include the physiological parameters of tracer uptake rate (Ki), metabolic rate of the tracer and total blood distribution volume (Vd) that allow for analyzing and visualizing the tracer accumulation over time, providing additional information that may help in the evaluation of SUV measurements on PET static images. The output of DynamicIQ is intended to be used by appropriately trained healthcare professionals as adjunct information for the review, analysis, and communication of PET static images for diagnosis, staging, treatment planning and monitoring. The parametric images should always be considered in addition to the conventional static PET images, which are the primary source to assist with diagnosis.

Technology:

The proposed device DynamiclQ employs the same fundamental scientific technology as its predicate device and reference devices.

Comparison:

The table below summarizes the key feature/technological differences and similarities between the predicate device and the proposed device:

Note: Proposed device DynamicIQ compares with "FlowMotion Multi - Parametric PET Al" which is a feature of Siemens Biograph Horizon PET/CT system (K193178). Other features of the predicate device are outside of the scope of the comparison.

Specification	Predicate Device:Biograph HorizonPET/CT (K193178)	Proposed Device:DynamicIQ	Comparison
Location ofProcessing	During scanning	Post-processing	Substantially Equivalent
Estimation of inputfunction fromblood pool scan	Yes	Yes	Substantially EquivalentBoth predicate and proposed device generatetracer Time Activity Curve (TAC) from bloodpool scan

{7}------------------------------------------------

Image /page/7/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' written in a stylized script inside a blue circle. There are decorative white swirls around the circle.

Estimation of inputfunction withoutblood pool scan	Yes	Yes	Substantially EquivalentPredicate and proposed device manage missinginput function case in different manners:Predicate uses manually inputted values whileproposed device uses Relative Patlak Analysis.
Output (AbsolutePatlak Analysis)	Yes	Yes	Identical.Generation of parametric images using Patlakmodel (Ki, Vd, Metabolic rate of FDG).
Output (RelativePatlak analysis)	Not applicable	Yes	Substantially EquivalentProposed device has Relative Patlak analysismode to deliver Relative tracer uptake rate Kiwhich has been shown to lead to visuallyidentical images to the Absolute Patlak analysis.Quantitative values are not available and Vd isnot available.
Result Review	Yes	Yes	Substantially EquivalentBoth applications can display static anddynamic PET images, CT and MR images (ifavailable). Both applications include aninteractive toolset to delineate findings andextract measurements from the static anddynamic PET images.

DynamicIQ is substantially equivalent to FlowMotion Multiparametric PET Al of Biograph Horizon PET/CT. The main differences between the proposed device and predicate device are:

-The proposed device is a standalone image post-processing software while the predicate is embedded into the Biograph Horizon PET/CT system.
-The proposed device performs a Relative Patlak analysis when a blood pool scan is not available as input, while the predicate requires a manual radiation titration to be entered to conduct the Patlak Analysis. The Relative Patlak analysis has been shown to lead to visually identical images to the Absolute Patlak analysis.

These differences do not raise new type of safety and effectiveness questions.

Determination of Substantial Equivalence:

Summary of Non-Clinical, Design Control Testing

DynamicIQ has successfully completed the design control testing per GE's quality system. It was designed and will be manufactured under the Quality System Regulations of 21CFR 820 and ISO 13485. No additional hazards were identified, and no unexpected test results were observed. The following quality assurance measures were applied to the development of the device:

{8}------------------------------------------------

Image /page/8/Picture/1 description: The image shows the logo for General Electric (GE). The logo consists of the letters "GE" in a stylized script, enclosed within a blue circle. There are decorative swirls around the circle, giving it a classic and recognizable appearance. The logo is simple, yet distinctive, and is widely associated with the multinational conglomerate.

Requirements Definition
Risk Analysis ●
Technical Design Reviews
Formal Design Reviews
Software Development Lifecycle ●
Performance testing (Verification, Validation)
Safety Testing (Verification)

The proposed DynamicIQ has been successfully verified on the AW VolumeShare workstation and AW Server platforms. Software documentation is for a MODERATE level of concern.

Conclusion:

DynamicIQ has substantial equivalent technological characteristics as its predicate device.

Based on development under GE Healthcare's quality system, successful design verification, software documentation for a "Moderate" level of concern, along with the engineering bench testing, GE Healthcare believes that the proposed DynamicIQ is substantially equivalent to, and hence as safe and as effective for its Intended Use as the legally marketed predicate device.

Regulation Number and Section

§ 892.1200 Emission computed tomography system.

(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.